Posted in | News | Business | Chemistry

UMED Enters Natural GTL Technology Commercialization Agreement

UMED Holdings, a Fort Worth, Texas-based company, declared that it has entered into a licensing deal for commercialization of new natural gas to liquid (GTL) technology, with the 1st Resource Group (1RG) and the University of Texas at Arlington (UT Arlington).

The technology to convert natural gas to clean synthetic fuels had been developed by UT Arlington and advanced by 1RG. The GTL conversion units, which are being developed in a modular, portable fashion, would enable natural gas manufactures to improve their financial outcome.

According to the agreement, UMED will be the primary source and the sub-licensee for commercializing the GTL conversion units. The company would generate revenues as and when the GTL units are deployed. 1RG would get warrants to acquire the common stock of UMED and would also receive additional consideration based upon specific sales.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chai, Cameron. (2019, February 09). UMED Enters Natural GTL Technology Commercialization Agreement. AZoM. Retrieved on November 24, 2024 from https://www.azom.com/news.aspx?newsID=29422.

  • MLA

    Chai, Cameron. "UMED Enters Natural GTL Technology Commercialization Agreement". AZoM. 24 November 2024. <https://www.azom.com/news.aspx?newsID=29422>.

  • Chicago

    Chai, Cameron. "UMED Enters Natural GTL Technology Commercialization Agreement". AZoM. https://www.azom.com/news.aspx?newsID=29422. (accessed November 24, 2024).

  • Harvard

    Chai, Cameron. 2019. UMED Enters Natural GTL Technology Commercialization Agreement. AZoM, viewed 24 November 2024, https://www.azom.com/news.aspx?newsID=29422.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.